Abstract
Tau aggregation is a defining histopathological feature of Alzheimer’s disease and other tauopathies. However, the cellular mechanisms involved in tau propagation remain unclear. Here, we performed an unbiased quantitative proteomic study to identify proteins that specifically interact with this tau seed. We identified Bassoon (BSN), a presynaptic scaffolding protein, as an interactor of the tau seed isolated from a mouse model of tauopathy, and from Alzheimer’s disease and progressive supranuclear palsy postmortem samples. We show that BSN exacerbates tau seeding and toxicity in both mouse and Drosophila models for tauopathy, and that BSN downregulation decreases tau spreading and overall disease pathology, rescuing synaptic and behavioral impairments and reducing brain atrophy. Our findings improve the understanding of how tau seeds can be stabilized by interactors such as BSN. Inhibiting tau-seed interactions is a potential new therapeutic approach for neurodegenerative tauopathies.
Similar content being viewed by others
Main
Pathological aggregation of tau is a defining histopathological feature of Alzheimer’s disease (AD), progressive supranuclear palsy (PSP) and many neurodegenerative diseases known as tauopathies1,2. A major focus of research has been to understand the propagation of pathological tau. Despite the knowledge acquired, the cellular mechanisms involved in tau propagation remain unclear, although reports have linked it to synaptic activity3,4,5. Tau released due to neuronal activity could be impaired by blocking presynaptic vesicle release3, suggesting that tau is released via presynaptic compartments. However, the nature of the tau species involved in tau spreading and the precise seeding mechanism and template remain unclear. Despite this uncertainty, some studies suggest that a rare species of soluble high-molecular-weight (HMW) tau is involved in trans-synaptic propagation6,7. Whether these HMW tau-containing particles exclusively comprise tau or contain other constituents, such as proteins or lipids for propagation, is unknown.
Numerous tau interactome-based studies have established that tau interacts directly with proteins and complexes involved in various biological functions in addition to those associated with microtubule stability8,9,10,11,12,13,14. Studies have also identified interactors of total tau in tauopathy mouse models15,16,17,18. Other studies have examined the interactome of total tau in human cell lines19,20 and induced pluripotent stem cell-derived neurons21. However, no studies have directly compared the interactomes of seeding-competent tau with those of monomeric tau or determined how tau-seed interactors affect the nature of this seed and, subsequently, tau propagation.
Here we performed unbiased quantitative mass spectrometry to characterize the tau species involved in tau propagation and identify proteins that specifically interact with the tau seed. Our results established that only a slight fraction of total tau in the brain forms a HMW complex with strong seeding activity. This tau seed interacts with proteins that do not interact with tau monomers. Bassoon (BSN), a scaffolding protein of the presynaptic active zone22, was identified as an interactor of this tau seed. We also identified BSN as an interactor of tau seeds isolated from AD and PSP postmortem samples. Our results demonstrate how BSN exacerbates tau seeding and toxicity in vitro and in vivo. Furthermore, BSN downregulation decreases tau spreading and rescues synaptic and behavioral impairment in a mouse model of tauopathy. Our findings highlight the importance of identifying tau interactors, such as BSN, that could act as stabilizers of the tau seed, enhancing its propagation and toxicity.
Results
BSN protein interacts with a high-molecular-weight tau seed
We characterized tau seeds from the PS19 mouse model that overexpresses human tau harboring the p.Pro301Ser (P301S) mutation23. To assess the molecular weight of the tau species involved in seeding activity, we performed size exclusion chromatography (SEC) on Tris-buffered saline (TBS)-soluble brain extracts from 3-month-old PS19 mice, representing an early stage of pathology. The tau-seeding activity of each SEC fraction was assessed by transfection into tau RD P301S fluorescence resonance energy transfer (FRET) biosensor cells and quantification of the integrated FRET density by flow cytometry24 (Fig. 1a and Extended Data Fig. 1a). The strongest seeding activity was found in the void volume fraction, fraction 9, which contained HMW proteins larger than 2,000 kDa (Fig. 1b). Fraction 9 contained only 5% of total tau, as assayed by enzyme-linked immunosorbent assay (ELISA) for human tau (Fig. 1c and Extended Data Fig. 1b,c). Interestingly, fraction 9 contained a low percentage of total tau even after treatment with the chaotropic denaturant guanidine hydrochloride (Gdn-HCl), which unmasks hidden epitopes25,26 (Extended Data Fig. 1b,c), meaning that the low total tau level detected in fraction 9 is not due to epitope masking in the HMW tau complex (Extended Data Fig. 1b,c). No seeding activity was observed in any SEC fractions from wild-type (WT) littermates (Fig. 1b).
a, Schematic of the tau-seeding assay of SEC fractions. b, Tau-seeding activity of SEC fractions obtained from 3-month-old PS19 and WT mouse brain lysates. c, Total human tau (hTau) detected by ELISA in SEC fractions from PS19 and WT mouse brain lysates. d, Tau-seeding activity of the PS19 SEC fraction 9 (F9) containing HMW tau, before and after hTau IP using HT7 antibody. e, EM of the F9 IP product showing short tau filaments, and width distribution of these filaments. Scale bar, 100 nm. The experiment was repeated three times with similar results. f,g, Volcano plot indicating tau interactors found in F9 (f) and F17 (g), identified by liquid chromatography coupled to tandem mass spectrometry (LC–MS/MS). h, Western blot of BSN from co-IP of human tau (HT7) from F9 in PS19 brain lysates. i, Representative immunofluorescence in PS19 mice cortex for pathological tau (PHF1) and BSN protein. Colocalized pixels are shown in white, whereas nuclei are visualized in cyan. The merged panel includes orthogonal images of reconstructed three-dimensional views. Colocalization analysis was performed to determine pixel intensity correlation between PHF1 and BSN. Scale bar, 25 µm. Data are shown as the mean ± s.e.m. Experiments were performed in triplicates (b–d, h and i), and significance was determined by an unpaired two-tailed Student’s t-test (d). CFP, cyan fluorescent protein; YFP, yellow fluorescent protein.
To confirm that the tau species present in fraction 9 is responsible for the seeding activity, we depleted human tau via immunoprecipitation (IP) using the HT7 antibody and observed a dramatic decrease in the seeding activity of the flow-through (Fig. 1d). Electron microscopy (EM) of the tau IP material from fraction 9 revealed that the seed takes on predominantly short filaments structure with a width of 7 ± 3 nm (Fig. 1e).
We performed IP of human tau from fraction 9 and fraction 17 (containing monomeric tau) using the HT7 antibody to identify protein interactors of the HMW tau seed and monomeric tau isolated from the same brain. The IP products were analyzed by a TMT-tags-based quantitative mass spectrometry workflow (Fig. 1f,g and Supplementary Data 1). DAVID functional annotation clustering revealed enrichment of synaptic terms in both interactomes (Supplementary Data 2). Interestingly, many synaptic proteins identified as tau-seed interactors differed from those that interacted with monomeric tau (Supplementary Data 2). We compared both interactomes with potential therapeutic targets for AD nominated by the AMP-AD in the ‘Wall of Targets’ (Supplementary Data 2)27,28. From this comparison, we identified BSN, a scaffolding protein of the presynaptic active zone involved in regulating synaptic neurotransmitter release22, presynaptic proteostasis and autophagy29,30,31, as a significant interactor of the tau seed. Surprisingly, missense mutations in the BSN gene have recently been identified in a family with pathological aggregation of 3R/4R tau32. Additionally, BSN expression is increased in patients with multiple system atrophy33 and BSN accumulates in patients with multiple sclerosis34.
We confirmed the interaction between BSN and tau seeds by co-immunoprecipitation (co-IP) in the SEC fraction 9 from PS19 mice (Fig. 1h). Double staining also revealed a strong colocalization of BSN with tau deposits in PS19 mice (Fig. 1i and Extended Data Fig. 2). The degree of colocalization between BSN and phosphorylated tau increased with age (Extended Data Fig. 2a,b). At later stages of tau pathology (9 months old), the colocalization of both signals appeared to be cytoplasmic, but at early stages (3 months old), the colocalization presented as diffuse puncta. Considering that BSN is mainly a presynaptic protein and tau has been identified at the presynapse at the early stage of pathology35,36, we performed triple staining for BSN, phospho-tau PHF1, and the presynaptic marker synapsin 1 (Syn-1) at 3 months, to show that BSN and phospho-tau colocalize at the presynaptic terminals (Extended Data Fig. 2c,d). These results suggest that at the early stages of pathology, the tau seed interacts with BSN at presynaptic compartments, and as the disease progresses, tau aggregates and BSN co-deposit in the cytoplasm.
BSN is associated with tau pathology in human tauopathy brain tissue
The tau species with the strongest seeding activity in AD and PSP patient brains was also a HMW tau species in fraction 9 (>2,000 kDa; Fig. 2a,b). As in the PS19 model, for both human tauopathies, tau in fraction 9 represented a small percentage of total tau in the brain (Fig. 2c,d). Interestingly, the age-matched controls had similar levels of tau in fraction 9 but lacked seeding activity (Fig. 2a–d). Depleting tau in fraction 9 from AD and PSP brains dramatically decreased seeding activity in the flow-through (Fig. 2e). EM of the tau IP material from fraction 9 revealed that in AD and PSP, the seeds were predominantly twisted filaments with widths of 6.95 ± 1.1 nm and 6.77 ± 1.4 nm, respectively (Fig. 2f,g). No tau filaments were detected when tau was immunoprecipitated from age-matched controls (Fig. 2f). We then confirmed by co-IP that, in both tauopathies, BSN interacts with tau in fraction 9 but does not interact with tau in fraction 9 from age-matched controls (Fig. 2h). Double staining revealed colocalization of BSN with tau deposits in AD and PSP brains (Fig. 2i and Extended Data Fig. 3).
a,b, Tau-seeding activity of SEC fractions from human AD lysates (from middle frontal gyrus, MFG; a) and PSP lysates (from pons; b), compared to healthy controls from MFG and pons, respectively. c,d, Total human tau detected by ELISA in SEC fractions from human AD (c) and PSP (d) brain lysates compared to healthy controls. e, Tau-seeding activity of the AD and PSP SEC fraction 9 (F9) containing HMW tau, before and after hTau IP using HT7 antibody. f,g, Tau twisted filaments present in the tau-IP product from F9 of AD and PSP SEC fractions, visualized by EM (scale bars, 100 nm; f), and width distribution (g). No filaments were detected in MFG and pons healthy controls. h, Co-IP of human tau (HT7) and BSN from SEC F9 in AD, PSP, control MFG and control pons brain lysates. i, Colocalization (yellow/white) between BSN (red) and pathological phosphorylated tau species (PHF1, green) in AD and PSP brain sections. The merged panel includes orthogonal images of reconstructed three-dimensional views. Colocalization analysis was performed to determine pixel intensity correlation between PHF1 and BSN. Scale bar, 10 µm. Data are shown as the mean ± s.e.m. Experiments were performed with n = 3 (a–d, f, h and i) and n = 6 (e). Significance was determined by unpaired two-tailed Student’s t-test (e).
BSN enhances tau-seeding activity and toxicity
We overexpressed human P301S tau in human embryonic kidney (HEK) 293T cells with and without human BSN to determine the effect of BSN on the pathological properties of tau. Lysates from cells overexpressing P301S tau with BSN demonstrated increased seeding activity compared to the lysate from cells overexpressing solely P301S tau (Fig. 3a). The overexpression of BSN was also associated with an increased accumulation of misfolded tau species (Fig. 3b). Double staining of HEK cells coexpressing BSN and P301S tau demonstrated that BSN co-deposits with misfolded tau species (Fig. 3c). In the same coexpression experiment, we confirmed by co-IP that BSN interacts with P301S tau (Fig. 3d). We performed a proximity ligation assay (PLA) on HEK cells to determine whether BSN interacts directly with tau. Cells coexpressing P301S tau and BSN showed a strong PLA signal, indicating that P301S tau and BSN are within interaction proximity (<40 nm; Fig. 3e). Considering that BSN interacts with the tau seed but not monomeric tau from PS19 mice (Fig. 1f,g) and with fraction 9 tau from patients with AD and PSP but not that from age-matched controls without seeding activity (Fig. 2h), we aimed to determine whether this interaction was conformation dependent. Because overexpressing a similar amount of human WT tau did not form stable aggregates and did not show the same seeding activity as human P301S tau (Extended Data Fig. 4a–c), we performed PLA on HEK cells coexpressing BSN and human WT tau to determine if BSN interacts with non-aggregating tau. Minimal PLA signal was observed in cells overexpressing WT tau and BSN (Fig. 3e), demonstrating that BSN has a higher affinity for tau when tau adopts a misfolded or aggregated conformation.
a, Seeding activity of HEK cell lysates expressing hTauP301S, BSNWT or both plasmids. b, Western blot and quantification of misfolded tau levels detected with MC1 antibody in HEK cells overexpressing hTauP301S, BSNWT or both. c, Representative image of double immunofluorescences between MC1 and BSN in HEK cells overexpressing hTauP301S and BSNWT. The merged panel includes orthogonal images of reconstructed three-dimensional views. Colocalization analysis was performed to determine pixel intensity correlation between MC1 and BSN. Scale bar, 50 µm. d, Co-IP of hTau (HT7 antibody) and immunoblot for BSN in HEK cells overexpressing hTauP301S and BSNWT. e, PLA fluorescence pairing of hTau and BSN antibodies, and quantification in HEK cells overexpressing TauWT, TauWT/BSNWT, TauP301S and TauP301S/BSNWT. f, PLA fluorescence pairing of hTau and His-tag antibodies, and quantification in HEK cells overexpressing TauP301S and TauP301S together with the N-terminal or C-terminal fragments of BSNWT (BSN-N or BSN-C, respectively). Scale bar, 50 µm. g–i, Representative images (g), quantification of phenotypic eye degeneration (h) and tau-seeding activity (each point is a pool of 20 fly heads from a distinct eclosion event; i), in control, BSNWT, BSNmut, hTauP301L, hTauP301L/BSNWT and hTauP301L/BSNmut flies. Data are the mean ± s.e.m. Experiments were performed with n = 8 (a–c), n = 3 (d), n = 5 (e and f), n = 20 (g and h) and n = 6 (i). Significance was determined by one-way analysis of variance (ANOVA; a, b, e, f, h and i). a.u., arbitrary units.
In the tau-seed analysis comprising immunoprecipitation followed by mass spectrometry (IP–MS; Fig. 1f), we identified BSN peptides corresponding to the N-terminal and the C-terminal regions of the BSN protein (Extended Data Fig. 4d), suggesting that the tau seed interacts with full-length BSN. We coexpressed P301S tau with the N-terminal fragment (1–850) or with the C-terminal fragment (2,450–3,942) of human BSN fused to a 6x-His tag in HEK cells, with both fragments expressed at a similar level (Extended Data Fig. 4e), to determine the region of BSN that interacts with aggregated tau. We then performed PLA and observed that cells co-transfected with P301S tau and BSN C-terminal fragment had a strong PLA signal (Fig. 3f), suggesting that BSN could interact with tau aggregates through its C-terminal region. Nevertheless, although significantly lower, PLA signals were observed in HEK cells co-transfected with P301S tau and BSN N-terminal fragment (Fig. 3f), suggesting that BSN could also interact with tau aggregates via its N-terminal region. Interestingly, it has been shown that large proteins with lower-than-average hydrophobicity, more intrinsically disordered residues and longer regions of disorder are more susceptible to aberrant interactions with amyloid-like aggregates37. Considering that BSN is a large protein that is almost entirely disordered34 (Extended Data Fig. 4f) and has a lower-than-average hydrophobicity (Extended Data Fig. 4g), BSN has the potential to engage in widespread aberrant interactions with aggregated forms of tau.
We overexpressed human BSN in two transgenic Drosophila melanogaster lines to investigate the effects of BSN upregulation in vivo, one line overexpressing WT BSN and the other overexpressing BSN harboring the p.Pro3866Ala mutation, recently identified in patients with pathological aggregation of 3R/4R tau32 (Extended Data Fig. 4h). Neither of these lines developed a degenerative eye phenotype (Fig. 3g). However, the overexpression of WT BSN enhanced the degenerative eye phenotype in the Drosophila model expressing human tau with the p.pro301leu mutation (hTau-P301L) by increasing the disruption of the ommatidial structure (Fig. 3g,h). The degenerative eye phenotype was intensified in the hTau-P301L fly when the BSN mutant was overexpressed (Fig. 3g,h). We confirmed by co-IP that WT and mutant BSN also interacted with tau in flies (Extended Data Fig. 4i). Western blotting showed that both WT and mutant BSN promoted the accumulation of the misfolded tau species, as detected by MC1 antibody (Extended Data Fig. 4j,k). We then used a guanidine stability assay to further examine stability differences between fly hTau-P301L aggregates. In the presence of WT and mutant BSN, tau aggregates were significantly more resistant to disaggregation by Gdn-HCl (Extended Data Fig. 4l,m). As observed in our cellular model, BSN overexpression in hTau-P301L flies led to an increase in tau-seeding activity, which was even higher with mutant BSN (Fig. 3i).
Bsn knockdown reduces tau spread in vivo
We then aimed to investigate whether BSN is critical for tau spreading in the brain using a well-characterized adeno-associated virus (AAV)-based spreading model. In this model, GFP and hTauP301L proteins are translated from mRNA-GFP-P2A-hTauP301L under the control of the cytomegalovirus promoter38. This model allows for discrimination between transduced neurons expressing both GFP and hTauP301L from those expressing only hTauP301L due to spreading38 (Fig. 4a). We performed neonatal (postnatal day (P) 0) intracerebroventricular injection of an AAV harboring a short-hairpin RNA (shRNA) against mouse Bsn (shBSN) or control ‘scramble’ shRNA in WT mice to downregulate the expression of Bsn in parallel. shBSN significantly downregulated Bsn (to ~60%) expression in vivo in WT mice (Extended Data Fig. 5a). Both scramble and shBSN shRNAs encode a blue fluorescent protein (BFP2) reporter, allowing the visualization of AAV transduction throughout the brain without producing gross abnormalities or negatively affecting presynaptic integrity (Extended Data Fig. 5b–d). Specifically, neonatal (P0) mice received intracerebroventricular injections of pAAV9-mTagBFP2-U6-mBsn-shRNA or control pAAV9-mTagBFP2-U6-Scr-shRNA, and, 3 months later, we administered stereotaxic injections of the pAAV-GFP-(P2A)-hTauP301L into the hippocampus. Three months after injection, the mice were euthanized, and tau spread was assessed by immunostaining using the anti-hTau HT7 antibody (Fig. 4b,c). Tau spreading was quantified in both groups by counting the number of hTau+/GFP− cells per mm2 (Fig. 4c,d). We observed substantial tau spreading in mice injected with scramble AAV, whereas spreading was significantly reduced in Bsn knockdown mice (Fig. 4d). This decrease was not due to differences in the number of transduced cells, as a comparable number of GFP-positive cells was observed in both groups (Fig. 4d).
a, Schematic of the GFP-P2A-hTauP301L tau-spreading mouse model. GFP+ neurons are hTau donors, spreading hTauP301L to recipient GFP− neurons. b, Timeline of injections in WT mice. Animals were injected with scramble or shBSN AAV at P0, then with AAV-GFP-P2A-hTauP301L at P90. Animals were euthanized at P180 to evaluate hTau spreading. c, Representative immunofluorescences for hTau (HT7 antibody) in animals overexpressing GFP-P2A-hTauP301L injected with scramble shRNA and BSN shRNA. Scale bar, 100 µm. d, Quantification of cortical hTau+/GFP− cells (top) and GFP+ cells (bottom) per mm2. For box plots, the center line represents the median, boundaries denote the interquartile range, and the whiskers represent the lower and upper limits. Values are given as the means ± s.e.m. Experiments were performed with n = 4, and significance was determined by unpaired two-tailed Student’s t-test.
Bsn downregulation reduced pathology and seed stability in vivo
We next investigated whether Bsn downregulation affects tau pathology and associated pathogenesis in PS19 mice. Neonatal PS19 and WT littermates were injected with an AAV encoding scramble or Bsn shRNA. Four months after injection, the mice were euthanized, and western blotting was conducted to confirm Bsn downregulation (Extended Data Fig. 6a,b). Detection of the anti-misfolded tau antibody (MC1) revealed that decreasing BSN levels reduced tau pathology in the hippocampus of PS19 mice (Fig. 5a,b). Microgliosis and astrogliosis were similarly decreased (Fig. 5c–e). The effect of Bsn downregulation on tau pathology and gliosis was significant in both female and male PS19 mice (Extended Data Fig. 6c–e). Western blotting in non-reducing conditions revealed that Bsn downregulation decreased phosphorylated tau aggregates (pTau; detected using PHF1 (pSer396/Ser404) and pThr231 antibodies) in the total lysate (Fig. 5f–h). ELISA revealed that Bsn downregulation did not influence total human tau levels in PS19 brains (Fig. 5i); however, a dramatic decrease in tau-seeding activity was observed (Fig. 5j). Bsn downregulation significantly decreased the levels of PHF1 aggregates, and seeding activity in females and males, but the effect on pThr231 tau levels was solely observed in male PS19 mice (Extended Data Fig. 6f–i). We then performed SEC on the brain lysates to determine if Bsn downregulation affects HMW tau-seed activity. As expected, the seeding activity of the fraction containing the HMW tau seed (fraction 9) was significantly lower in PS19shBSN than in PS19scramble samples (Fig. 5k). Interestingly, a similar distribution of total tau levels was observed in the SEC fractions of PS19shBSN and PS19scramble mice (Fig. 5l), suggesting that BSN plays a minimal role in the formation of HMW tau complexes but instead affects the properties of the tau seed by enhancing its seeding activity, perhaps by stabilizing and promoting HMW tau-seed aggregation. SEC fractions were analyzed by western blot with strong reducing conditions to test this hypothesis. Tau remained at the top of the gel in the HMW fractions (F8, F9 and F10) in samples from PS19scramble, but in samples from PS19shBSN, HMW tau was resolved in the gel as a monomer (Fig. 5m). When using the MC1 antibody, tau again remained at the top of the gel in HMW SEC fractions in PS19scramble samples, but in PS19shBSN samples, no misfolded tau was observed in the HMW SEC fractions in strong reducing conditions (Fig. 5m). These data suggest that BSN stabilizes HMW tau aggregates, increasing their resistance to degradation in reducing conditions. We assessed the proteinase K (PK) sensitivity of misfolded tau in brain sections from PS19scramble and PS19shBSN mice to further explore if BSN affects the structural properties of tau aggregates. Misfolded tau detected by MC1 in PS19shBSN samples was considerably more sensitive to protease degradation, with the intensity dramatically decreased after 45 s of PK digestion (Extended Data Fig. 7). This result suggests that in the absence of BSN, tau aggregates have a relaxed structure and are accessible for digestion, whereas in the presence of BSN, tau aggregates are more compacted and resistant to PK.
a, Representative images of hippocampal MC1 immunostaining in 4-month-old PS19 mice injected with shBSN and scramble shRNA. Scale bars, 200 µm and 50 µm for CA1 and CA3 insets, respectively. b, Quantification of MC1 immunostainings in shBSN and scramble PS19 mice as a percentage of area. c–e, Hippocampal immunofluorescence (c), using specific antibodies against GFAP (red) and IBA1 (green) in WTscramble, WTshBSN, PS19scramble and PS19shBSN mice. Quantification was performed as a percentage of area for IBA1+ (d) and GFAP+ (e) cells. f–h, Western blot (f), and quantification of specific antibodies against pTau-Ser396/Ser404 (PHF1; g), and pTau-Thr231 (h), in shBSN and scramble PS19 mouse brain. i,j, Total human tau levels measured by ELISA (i), and tau-seeding activity (j), in shBSN and scrambled shRNA PS19 mouse brain lysates. k,l, Seeding activity (k) and total hTau levels (l) in SEC fractions from shBSN or scramble PS19 mouse brain lysates. m, Western blot of total tau (HT7, top blot) and misfolded tau (MC1, bottom blot) in SEC fractions (fractions 7 to 10, HMW; fractions 14 to 17, low molecular weight (LMW)) from shBSN and scramble PS19 mouse brain lysates. The experiment was repeated three times with similar results. n, Representative merge images of immunofluorescence of PSD95 (green), Syn-1 (magenta) and colocalized pixels (white). The merged panel includes orthogonal images of reconstructed three-dimensional views. Colocalization analysis was performed to determine pixel intensity correlation between PSD95 and Syn-1. o, Colocalization quantification by Pearson’s correlation coefficient. Data are the mean ± s.e.m. Experiments were performed with n = 8 (a–j, n and o), n = 6 (k and l) and n = 3 (m). Significance was determined by unpaired two-tailed Student’s t-test (b and g–k) and one-way ANOVA (d, e and o).
Because synaptic loss occurs as early as 3 months of age in PS19 mice23, we assessed whether the decrease in tau pathology after Bsn downregulation corresponded to improved synaptic integrity in 4-month-old PS19 mice. Quantification of the colocalization of presynaptic (Syn-1) and postsynaptic (PSD95) marker puncta in the cortex of PS19scramble and PS19shBSN mice (Fig. 5n) revealed a significant improvement in synaptic integrity in PS19shBSN mice (Fig. 5o and Extended Data Fig. 8a). The effect of Bsn downregulation on synaptic integrity in PS19 mice could be due to a decrease in the accumulation of misfolded tau at the presynapse (Extended Data Fig. 8b,c).
Reducing BSN rescues the phenotypes in a tauopathy mouse model
A second cohort of 6-month-old PS19 and WT littermates were injected at P0 with scramble or Bsn shRNA to determine if this synaptic integrity rescue represented a functional improvement. We measured long-term potentiation (LTP) in the CA1 hippocampal area in mouse brain slices. We monitored field excitatory postsynaptic potentials (fEPSPs) evoked by extracellular stimulation of the Schaffer collateral pathway and induced LTP using high-frequency stimulation (four stimuli of 100 Hz for 1 s with a 10-s interstimulus interval). Severely impaired hippocampal LTP was observed in PS19scramble mice versus WTscramble and WTshBSN mice; however, a decrease in BSN levels in PS19shBSN mice rescued LTP (Fig. 6a–c). We observed no difference in LTP between the PS19shBSN mice and the WTscramble or WTshBSN controls. We also measured the paired-pulse ratio (PPR), which decreased in PS19scramble mice versus WTscramble and WTshBSN animals, reflecting diminished synaptic vesicular release probability. This reduction was rescued in PS19shBSN animals (Fig. 6d). The beneficial effect of Bsn downregulation on LTP and PPR was observed in both female and male PS19 mice (Extended Data Fig. 9a,b).
a, Superimposed fEPSP traces produced by stimulation of the Schaffer collateral pathway and recorded in CA1 brain slices before (gray dashed lines) and after (gray, orange, black and light blue lines) LTP induction. Vertical bar, 300 mV; horizontal bar, 10 ms. b–d, Summary of in vivo LTP (b), averaged from minute 60 to 70 (c), and PPR (d), in 6-month-old WT and PS19 mice injected with shBSN or scramble shRNA. Data represent the mean ± s.e.m. Experiments were performed with n = 11 for WTscramble, n = 11 for PS19scramble, n = 10 for WTshBSN and n = 11 for PS19shBSN mice (b–d). Significance was determined by two-way ANOVA (c and d).
A third cohort of 9-month-old mice was subjected to behavioral and physiological tests to further assess the functional benefit of Bsn downregulation. As we recently demonstrated a decrease in motor strength in PS19 mice39, the grip strength of the front two paws and all four paws were tested. PS19scramble mice exhibited reduced two-paw and four-paw grip strength compared to WTscramble and WTshBSN mice (Fig. 7a,b). There were no differences between PS19shBSN mice and WTscramble or WTshBSN mice, suggesting that Bsn downregulation rescues motor impairment. The physiological characteristics were evaluated by measuring the basal core body temperature and frailty markers. PS19scramble mice had lower basal body temperatures than the WTscramble and WTshBSN mice; however, downregulation of Bsn levels completely rescued the decreased body temperature in PS19shBSN mice (Fig. 7c). We then performed a clinical exam to assess the 26 frailty parameters39. PS19scramble mice exhibited more frailty markers than WTscramble and WTshBSN mice (Fig. 7d), indicating a decline in general health. No differences were observed between PS19shBsn mice and either WT group, indicating the benefit of Bsn downregulation in the context of tau pathology. Motor and physiological rescue by Bsn downregulation were observed in both male and female PS19 mice (Extended Data Fig. 9c–f).
a–d, Two-paw test (a), four-paw test (b), body temperature (c) and frailty test (d) in 9-month-old WT and PS19 mice injected with shBSN or scramble shRNA. e, Hippocampal MC1 immunostaining in 9-month-old PS19 mice injected with shBSN and scramble shRNA. Scale bars, 200 µm and 50 µm for CA1 and CA3 insets, respectively. f, Quantification of MC1 immunostaining in shBSN and scramble PS19 mice as a percentage of area. g–i, Western blot (g), and quantification of specific antibodies against pTau-Ser396/Ser404 (PHF1; h), and pTau-Thr231 (i), in shBSN and scramble PS19 mouse brain lysates. j, Total human tau levels by ELISA in shBSN and scrambled PS19 mouse brain lysates. Experiments were performed with n = 20 for WTscramble, n = 21 for PS19scramble, n = 22 for WTshBSN and n = 16 for PS19shBSN mice (a–d), and n = 8 (e–j). Significance was determined by one-way ANOVA (a–d) and unpaired two-tailed Student’s t-test (f and h–j). Bar graphs with error bars indicate the mean ± s.e.m.
We next tested whether Bsn downregulation could reduce neurodegeneration in PS19 mice. As rising ventricular volumes and a decline in hippocampal volume indicate brain atrophy in 9-month-old PS19 mice40, we determined the effect of Bsn downregulation on ventricular and hippocampal volume by volumetric magnetic resonance imaging MRI analysis. Bsn downregulation did not significantly alter the ventricular nor hippocampal volume in WT mice (Extended Data Fig. 10a–c). PS19scramble mice exhibited an increase in ventricular volume and a decline in hippocampal volume compared to the WTscramble and WTshBSN mice (Extended Data Fig. 10a–c). However, decreasing BSN levels in PS19 mice significantly ameliorated the ventricular volume increase compared to PS19scramble mice (Extended Data Fig. 10a–c). No differences were observed in hippocampal volume between PS19shBSN mice and WTscramble or WTshBSN mice, suggesting that Bsn downregulation partially reduces neurodegeneration in tauopathies. Due to the limited number of mice, it was not possible to determine sex differences in the beneficial effects of Bsn downregulation on restoring ventricular and hippocampal volume. Finally, we evaluated whether the functional improvement and rescue of brain atrophy observed in 9-month-old PS19 mice were associated with decreased pathological tau burden. Immunofluorescence analysis revealed that Bsn downregulation reduced tau pathology in the hippocampus of PS19 mice (Fig. 7e,f). Using western blotting, we also confirmed that downregulation of Bsn decreased phosphorylated tau aggregates (Fig. 7g–i) but did not affect total tau levels measured by ELISA in brain samples from 9-month-old PS19 mice (Fig. 7j). The decrease in pathological tau burden was significantly observed in 9-month-old female and male PS19 mice (Extended Data Fig. 9g–j), suggesting that the effect of Bsn downregulation on early stages of tau aggregation (Fig. 5) has lasting effects on tau burden when higher levels of pathology have developed.
Discussion
We identified BSN as a tau-seed interactor exhibiting a preponderant role in tau-seed stability and spreading. Downregulating Bsn significantly reduced tau spreading and overall tau pathology, improved synaptic integrity, rescued electrophysiological and behavioral impairments and reduced brain atrophy. BSN is a large scaffolding protein (419 kDa) of the presynaptic active zone involved in the regulation of neurotransmitter release at the synapse22. Mice with constitutive ablation of the bassoon gene show no abnormalities in brain architecture but have impaired presynaptic functions41. Interestingly, partial loss of Bsn (Bsn+/−) causes no abnormalities, suggesting that a 50% decrease in Bsn levels is well tolerated41. The recently developed BsnfloxP/floxP mouse model34 shows no neuronal differences from constitutive knockout allele by Cre-mediated recombination in the germ line and WT controls, suggesting that ablation of Bsn is not detrimental. BSN also regulates presynaptic ubiquitination, proteostasis and autophagy29,30. Synaptic accumulation of tau aggregates in AD is associated with dysfunction of the ubiquitin–proteasome system, suggesting that these aggregates may be an important mediator of the proteotoxicity that disrupts synapses in AD42. BSN is also involved in regulating neurotransmitter release from glutamatergic synapses41. The selective ablation of Bsn in excitatory neurons enhances learning performance in mice22. Little is known about the importance of BSN in tau pathology and neurodegeneration. The strongest evidence linking BSN with tau pathology was published in 2018, revealing four missense mutations in the BSN gene (p.Pro3866Ala) and aggregation of three-repeat and four-repeat tau in patients32. Another study revealed increased BSN expression in patients with multiple system atrophy33, a neurodegenerative disease characterized by the aggregation of alpha-synuclein and tau protein43. A new study recently demonstrated the toxic accumulation of BSN in the neuronal somata of mice and patients with multiple sclerosis34. Notably, this study also demonstrated that the genetic ablation of Bsn protected mice from inflammation-induced neuroaxonal injury and enhanced neuronal survival34. Overall, these studies suggest associations among BSN, neurodegenerative events and tau pathology, and support the feasibility of BSN downregulation as a therapeutic avenue for neurodegenerative tauopathies.
Apart from BSN, we also identified other presynaptic interactors. The association between the tau seed and presynaptic proteins is relevant considering that numerous studies have suggested that secreted tau can spread among synaptically connected neurons5,44. Tracy et al.21 recently demonstrated that WT tau interacts with numerous presynaptic proteins at the active zone in human induced pluripotent stem cell-derived neurons. The authors demonstrated that neuronal activity enhanced the interaction of tau with synaptic vesicle proteins, suggesting that presynaptic fusion machinery could regulate activity-dependent tau release through direct protein–protein interaction. The authors observed that tau interacts with synaptotagmin-1 (SYT1) and an increase in neuronal activity enhanced the interaction of tau with SYT1. Interestingly, we identified SYT1 as an interactor of the tau seed (Supplementary Data 2), supporting the notion that the tau seed interacts with presynaptic proteins strongly associated with physiological tau during neuronal activity. In our study, we also identified synaptogyrin-3 (SYNGR3) as an interactor of the tau seed and monomeric tau (Supplementary Data 2). Additionally, it has been previously shown that tau interaction with SYNGR3 inhibits presynaptic vesicle release, and SYNGR3 downregulation rescues tau-induced defects in a mouse model of tauopathy11, supporting the beneficial effects of downregulating the levels of a presynaptic tau interactor. Together with previous work, our study supports the relevance of presynaptic tau interactors in disease pathogenesis via a diverse set of mechanisms that are not mutually exclusive. One mechanism could involve increased stability or resistance to degradation of a toxic tau conformer due to its interaction with presynaptic proteins. Another possibility involves the loss of physiological synaptic functions due to the interaction of these synaptic proteins with tau aggregates. A third possibility is that a tau conformer with seeding activity utilizes the presynaptic vesicle fusion machinery for neuronal release, as suggested for physiological tau21, through aberrant protein interactions. In our study, we focused on the presynaptic protein BSN as a new interactor of the tau seed, considering the strong genetic link between BSN mutation and human tauopathies32. Nevertheless, further studies are necessary to determine the relevance of the presynaptic machinery in tau-seed propagation and overall pathogenesis.
The formation of pathological aggregates is likely driven by multiple processes involving complex interactions between the disease-associated proteins and other proteins45. It has been proposed that flexible hydrophobic surfaces enable soluble aggregates to engage in aberrant interactions with metastable proteins that share distinct physicochemical properties37. Proteins prone to interact with aggregates are usually larger, have a lower average hydrophobicity and exhibit high structural flexibility; additionally, they have significant enrichments in intrinsically disordered regions37. BSN, a large multidomain protein with long stretches of intrinsically disordered residues, is particularly prone to accumulation34; thus, BSN could interact with amyloid-like aggregates. Previous studies identified tau interactors from total cellular or brain lysate without discerning between tau aggregation state15,16,17,18,19,20,21, which may have masked the effect of proteins, such as BSN, that solely interact with the tau seed. Amyloid-like aggregates were originally reported to exert toxicity, in part, by interacting with and sequestering functional proteins, leading to the collapse of essential cellular functions37. Nevertheless, it was recently suggested that tau aggregates in the brain are stabilized by unknown cofactors that lead to higher-quality packing46. Our results indicate that BSN might contribute to tau pathogenesis by promoting the stabilization and resistance to degradation of abnormal tau structures and assemblies with strong seeding activity. Nonetheless, we cannot rule out that BSN dysfunction affects the regulation of neurotransmitter release41 or presynaptic proteostasis29,30, which could contribute to tau-related toxicity.
Recent breakthroughs in cryo-EM have yielded atomic structures of tau filaments upon sarkosyl extraction from brains of individuals with various tauopathies, demonstrating that each disease is characterized by a unique tau filament fold47. Considering this structural heterogeneity between tauopathies, further studies using approaches such as cryo-EM and immuno-EM48 would be important to determine structural and morphological differences between tau seeds isolated from patients with AD, patients with PSP and PS19 mice.
In summary, our findings improve the understanding of the nature of the tau seed, highlighting the importance of identifying interactors, such as BSN, that could work as scaffolds or stabilizers of the pathogenic seed. The inhibition of these interactions could be a new therapeutic approach for neurodegenerative tauopathies.
Methods
Mice
All work involving mice was performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health (NIH)) and procedures approved by the Indiana University School of Medicine (IUSM) Institutional Animal Care and Use Committee. Mice were bred and housed at the IUSM animal care facility and were maintained according to US Department of Agriculture standards (12-h light/dark cycle, food and water ad libitum, ~25 °C, 40–60% humidity) in accordance with the Guide for the Care and Use of Laboratory Animals (NIH). The PS19 mouse model, which overexpresses human 1N4R tau with the P301S mutation on the C57B6/J background, was directly purchased from The Jackson Laboratory (stock no. 008169). For all described experiments, 4-month-old, 6-month-old and 9-month-old PS19 and WT littermates of both sexes were utilized. All mice were randomly assigned to treatment and experimental groups.
Human tissue samples
Frozen samples consisting of blocks of postmortem brain tissues from individuals with AD, individuals with PSP and controls were provided by the Brain Resource Center at Johns Hopkins. AD cases consisted of pathologically severe AD, stage V–VI (Supplementary Data 1).
Preparation of Tris-buffered saline-soluble homogenates
Each brain tissue was homogenized in TBS buffer at a ratio of 1:10 (wt/vol) with a protease inhibitor cocktail (Roche, 11873580001). Samples were then centrifuged at maximum speed for 15 min at 4 °C. The supernatants were portioned into aliquots, snap frozen and stored at −80 °C until analyzed.
Size exclusion chromatography
SEC was performed with a Superose 6 Increase 10/300 GL column (GE Healthcare, 29091596) on an ÄKTA pure 25 L chromatography system (GE Healthcare, 29018224). The column was equilibrated with 1.5 CV of a 50 mM NaCl, 50 mM Tris pH 8.0 buffer at a flow rate of 0.7 ml min−1. Samples were clarified by centrifugation at 10,000g for 10 min. Protein concentration was quantified by Bradford assay, and 1–5 mg total protein of supernatant was taken for separation, depending on the sample. The supernatant was concentrated with a 0.5-ml 3K Amicon centrifugal filter (Millipore Sigma, UFC5003) to ~200 µl, then loaded onto the column via sample loop injection. Starting from injection, 1-ml fractions were collected into tubes containing EDTA-free protease inhibitor (Roche, 11873580001) at a flow rate of 0.3 ml min−1.
Tau-seeding assay
The seeding assay was performed as previously described24 with minor modifications. TauRD P301S FRET Biosensor cells (American Type Culture Collection (ATCC), CRL-3275) were plated at 35,000 cells per well in 130 µl medium in a 96-well plate, then incubated at 37 °C overnight. The next day, cells were transfected with cell or brain lysate (20 µg total protein per well) by using Lipofectamine 2000 and then incubated at 37 °C for 48 h. Cells were harvested by trypsinization. Flow cytometry was conducted with a BD LSRFortessa X-20 with a High Throughput Sampler, using the BD FACS Diva (v8.0) software. FlowJo (v10.0) was used for data analysis. The BV421 channel (excitation of 405 nm, emission of 450/50 nm) was used to detect CFP, and the BV510 channel (excitation of 405 nm, emission of 525/50 nm + 505LP) was used to detect FRET signal, with compensation to remove the CFP spillover into the FRET channel. Data analysis was performed with FlowJo, using the gating strategy shown in Extended Data Fig. 1a. Seeding was quantified by integrated FRET density, defined as the product of the percentage of FRET-positive cells and median fluorescence intensity of FRET-positive cells.
Human tau ELISA
ELISA was performed on SEC fractions using Tau (Total) Human ELISA Kit (Invitrogen, KHB0041) by following the directions provided by the manufacturer. Lysates were diluted 1:50,000 in blocking buffer. F7–F14 were diluted at a ratio of 1:2,000 in blocking buffer. F15–F22 were diluted at a ratio of 1:20,000 in blocking buffer.
Guanidine hydrochloride denaturation assay
Each sample was diluted to the same protein concentration by Bradford assay. Samples were denatured by adding a Gdn-HCl solution at a 1:1 ratio by volume, varying the initial concentration of the Gdn-HCl solution to obtain the desired final concentration after mixing. The mixture was incubated for 30 min at room temperature (RT). After incubation, the mixture was diluted for ELISA or western blot immediately. To control for the potential effect of trace amounts (<5 mM) of Gdn-HCl on the ELISA assay, a 1 ng ml−1 tau standard was also spiked with Gdn-HCl at a concentration matching that of each sample. The effect of trace Gdn-HCl on the assayed ELISA concentration was not statistically significant.
Immunoprecipitation
From HEK293T lysates, SEC fraction 9 from PS19 mice, and AD and PSP human samples, tau was immunoprecipitated by using 2 µg of biotinylated HT7 antibody (Thermo Fisher, MN1000b), for every 100 ng of human tau quantified by ELISA. IgG isotype control antibodies (BioLegend, 400104) were used for comparison. The IP and flow-through samples were then subjected to further analysis.
Electron microscopy
IP samples were analyzed by negative-stain biological transmission EM as described before49. Briefly, 3 µl of the IP sample was directly pipetted on discharged carbon-coated copper transmission EM grids and incubated for 1 min. Grids were carefully washed with deionized water without letting it dry and stained with 3.5 μl of 1% (wt/vol) phosphotungstic acid solution for 1 min. Any excess solution was then removed by blotting with a Whatman filter paper. The samples were imaged using an FEI Tecnai T12 transmission electron microscope operating at 80 kV. Images were captured using Gatan digital micrograph software and the width was measured using image analysis software ImageJ. Three independent samples were analyzed, and results were plotted with Prism 9.0 software.
Mass spectrometry
Sample preparation for the affinity purification mass spectrometry experiments was designed at the Proteomics Core Facility of IUSM from previously reported qPLEX-RIME methodology that have integrated isobaric labeling and tribrid mass spectrometry methods with RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins) with modifications50,51,52. Briefly, magnetic beads, affinity captured with proteins, were treated with 10 μl trypsin/LysC (15 ng µl−1; Promega Corporation) in 100 mM ammonium bicarbonate and incubated overnight at 37 °C with shaking, followed by a second digestion with trypsin/LysC at RT for 4 h. The magnetic beads were next separated on a magnetic stand to separate the supernatant peptide solution. De-salting was carried out using Sep-Pak Vac 1 cc C18 cartridges (Waters Corporation) using a vacuum manifold. All samples were then dried using a SpeedVac, reconstituted in 50 mM triethylammonium bicarbonate and subjected to tandem mass tags (TMT)-based labeling using TMT10plex reagents (Thermo Fisher, 90309). Next, Nano-LC–MS/MS analyses were performed on an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) coupled to an EASY-nLC HPLC system (Thermo Scientific). Labeled, mixed and dried peptide samples were reconstituted in 0.1% formic acid (FA; 20 μl) and 8 μl equivalent volume was loaded onto a reversed-phase PepMap RSLC C18 column (2 μm, 100 Å, 75 μm × 50 cm) with Easy-Spray tip using an applied maximum pressure of 750 bar. The peptides were eluted using a varying mobile phase (MP) gradient from 94% phase A (FA/H2O 0.1/99.9, vol/vol) to 28% phase B (FA/acetonitrile 0.1/99.9, vol/vol) for 160 min; to 35% phase B for 5 min; to 50% phase B for 14 min to ensure elution of all peptides and bringing down the MP composition to 10% phase B for 1 min at 400 nl min−1 to bring the MP composition to a higher percentage of phase A. Nano-LC MP was introduced into the mass spectrometer using an EASY-Spray Source (Thermo Scientific). During peptide elution, the heated capillary temperature was kept at 275 °C and ion spray voltage was kept at 2.6 kV. The mass spectrometer method was operated in positive ion mode for 180 min with a cycle time of 4 s. Mass spectrometry data were acquired using a data-dependent acquisition method that was programmed to have two data-dependent scan events following the first survey mass spectrometry scan. During MSn level 1, using a wide quadrupole isolation, survey scans were obtained with an Orbitrap in the range of 375–1,500 m/z at 60,000 resolution. To isolate and fragment the selected precursor ions, MSn level 2 scans were performed with following vendor defined parameters: isolation mode, quadrupole; isolation offset, off; isolation window, 0.8; multi-notch isolation, false; scan range mode, auto normal; first mass, 100; activation type, higher-energy collisional dissociation; collision energy mode, fixed; collision energy (%), 38; detector type, orbitrap; orbitrap resolution, 50,000; maximum injection time, 90 ms; automatic gain control target, 1E5; data type, centroid; polarity, positive; source fragmentation, false. The data were recorded using Thermo Scientific Xcalibur (4.1.31.9; 2017) software. Resulting RAW files were analyzed using Proteome Discover 2.2.0.388 (Thermo Fisher Scientific). The MS/MS spectra were searched against in silico tryptic digest of a database (FASTA) downloaded from UniProt (mouse_human_uniprot_contam_030419.fasta) using the SEQUEST HT search engine. The following search parameters were applied: trypsin as the proteolytic enzyme; peptides with a maximum number of 2 missed cleavages, precursor mass tolerance of 10 ppm, and a fragment mass tolerance of 0.6 Da. Static modifications used for the search were: (1) carbamidomethylation on cysteine residues; (2) TMT sixplex label on lysine residues and the N termini of peptides. Dynamic modifications used for the search were: oxidation of methionines and phosphorylation of S/T/Y. Percolator false discovery rate (pFDR) was set to a strict setting of 0.01 and a relaxed setting of 0.05. Values from both unique and razor peptides were used for quantification.
Enrichment analysis
Abundance ratios of HT7 IP were compared with control IgG IP to determine protein enrichment levels (n = 3). Proteins enriched by a fold change > 4 with P < 0.05 by t-test (total of 1,159 in tau seed and 365 in tau monomer) were selected for DAVID functional annotation (https://david.ncifcrf.gov/) using default settings with the mouse genome. We then compared both interactomes with the ‘Wall of Targets’ nominated by the AMP-AD as possible targets for AD (https://agora.ampadportal.org/genes/(genes-router:genes-list)). Synaptic proteins were identified by searching Gene Ontology for genes that have a ‘part of’ or ‘regulate’ transitive closure relation with the synapse term (GO:0045202).
Immunohistochemistry and proteinase K sensitivity assay
Slides were deparaffinized and rehydrated in several incubations of xylene, ethanol gradient (100% to 30%) and deionized water. The slides were stained with hematoxylin and eosin (Vector Labs, H-3502) following the manufacturer’s protocol. Slides were subsequently dehydrated, coverslipped and imaged.
For PK sensitivity assay, following antigen retrieval, the slides were incubated with 50 μg ml−1 PK (Bioline, BIO-37037), 10 mM Tris HCl pH 7.8, 100 mM NaCl, 0.1% NP-40 at 37 °C for 0 s, 10 s and 45 s, similarly to what was described before53.
Disorder and hydrophobicity profile
Disordered residues were predicted by ESpritz54 using the DisProt database. The optimal binary decision threshold Sw was used as the threshold for disorder. The hydrophobicity profile was calculated using the method of Kyte & Doolittle55 with a moving average window of nine residues.
Immunofluorescences
Mouse paraffin sections were deparaffinized in xylene, rehydrated in ethanol gradient (100% to 30%) and washed with deionized water. Then, the sections were heated to 95 °C in high pH antigen retrieval solution (Invitrogen eBioscience, 00-4956-58) for 10 min with a microwave oven. After washing twice with PBS (5 min each), the sections were incubated with TrueBlack (Biotium, 23007) for 3 min and then washed three times in PBS. Then, tissues were blocked with PBS 10% goat serum and 0.01% Triton X-100 for 1 h at RT. Sections were then incubated overnight at 4 °C with the following primary antibodies: HT7 (Thermo Fisher, MN1000; 1:300 dilution), anti-Bassoon (Millipore, ABN255; 1:300 dilution), anti-GFP (Abcam, ab1218; 1:1,000 dilution), MC1 (Peter Davies; 1:300 dilution), PHF1 (Peter Davies; 1:300 dilution), anti-GFAP (Sigma-Aldrich, G3893; 1:100 dilution), anti-IBA1 (Wako, 019-19741; 1:100 dilution)), 6x-His (Thermo Fisher MA1-1351:300), PSD95 (Abcam, ab2723; 1:100 dilution) and Syn-1 (Abcam, ab64581; 1:100 dilution). The next day, sections were quickly washed three times in PBS and incubated for 2.5 h with a 1:500 ratio of Alexa Fluor antibodies (goat anti-rabbit Alexa Fluor 488 (Invitrogen, A11008; 1:200 dilution), goat anti-mouse Alexa Fluor 488 (Invitrogen, A32723; 1:200 dilution), goat anti-rabbit Alexa Fluor 568 (Invitrogen, A11036; 1:200 dilution), goat anti-mouse Alexa Fluor 568 (Invitrogen, A11031,1:200 dilution)), diluted in blocking solution. Sections were quickly washed three more times in PBS and mounted with Fluoromount (Sigma, F4680). For AD and PSP cases, frozen sections were first fixed with 4% paraformaldehyde for 1 h at RT and then permeabilized in Triton X-100 0.01% for 1 h, continuing with the mentioned immunofluorescence protocol. For cell immunofluorescences, HEK293T cells were fixed in 4% paraformaldehyde for 30 min and washed three times for 5 min with 1× PBS. Cells were permeabilized with 0.01% Triton X for 20 min at RT and washed three times with 1× PBS. Coverslips were incubated with 10% Normal Goat Serum and blocked for 30 min at RT. Then, the coverslips were incubated with primary antibodies (MC1 (Peter Davies; 1:300 dilution) and anti-Bassoon (Millipore, ABN255; 1:300 dilution)) diluted in 10% normal goat serum overnight at 4 °C. The next day, coverslips were washed three times with 1× PBS and incubated with Alexa secondary antibodies (goat anti-mouse Alexa Fluor 488 (Invitrogen, A32723; 1:200 dilution) and goat anti-rabbit Alexa Fluor 568 (Invitrogen, A11036; 1:200 dilution)), diluted in 10% normal goat serum for 2 h at RT. Coverslips were then washed three times with 1× PBS and mounted using Fluoromount (Sigma, F4680).
Proximity ligation assay
HEK293T cells (ATCC, CRL-3216) were grown on coverslips and transfected with plasmids encoding TauWT, TauP301S, full-length BSNWT and BSN N-terminal and C-terminal fragments. At 72 h later, cells were fixed in 4% paraformaldehyde for 30 min and washed three times for 5 min with PBS. PLA was performed using the Duolink In Situ Fluorescence kit (Sigma, DUO92101) according to the manufacturer’s instructions. Briefly, the coverslips were incubated with the Duolink Blocking solution for 1 h at 37 °C in a humidified chamber. Then, the blocking solution was removed, and coverslips were incubated with primary antibodies (MC1 (Peter Davies; 1:300 dilution), anti-Bassoon (Millipore, ABN255; 1:300 dilution), anti-total tau (DAKO, A0024; 1:300 dilution) and 6x-His (Thermo Fisher, MA1-135; 1:300 dilution)) diluted in Duolink Antibody Diluent overnight at 4 °C. The coverslips were then washed with wash buffer A (Sigma) twice for 5 min. Then, the Duolink In Situ PLA Probe Anti-Rabbit PLUS and Duolink In Situ PLA Probe Anti-Mouse MINUS PLA probes (Sigma) diluted in Duolink Antibody Diluent were applied to the coverslips and incubated in a humidified chamber for 1 h at 37 °C. Coverslips were washed twice with wash buffer A, followed by incubation with the ligation solution for 30 min at 37 °C, then washed twice with buffer A and incubated with amplification solution for 100 min at 37 °C. Finally, the coverslips were washed twice for 10 min in buffer B (Sigma), once in 0.01% buffer B and then mounted onto the slides using the Duolink In Situ Mounting Medium with DAPI (Sigma). The edges were sealed with clear nail polish.
Imaging and analysis
Mice sections were imaged with a Nikon A1-R laser scanning confocal microscope coupled with Nikon AR software. For tau propagation analysis, images (z-stack step size of 0.5 µm) were imported into ImageJ (NIH). Propagation analysis was performed by counting HT7+/GFP− or GFP+ cells per 1 mm2. For functional synapsis analysis, image stacks (0.1 µm) were imported into ImageJ, and colocalization was quantified by Pearson’s correlation coefficient using the JACoP plug-in.
Cell culture co-transfection
HEK293T cells (ATCC, CRL-3216) were cultured in DMEM (Invitrogen) with 10% FBS (Invitrogen). Human Tau-P301L/WT and WT human Bassoon were cloned in pRK5 and CMV plasmid (Vector Builder), respectively. Plasmids were transfected, in 1:10 dilution of Tau:BSN, with Lipofectamine 3000 (Invitrogen) and incubated for 72 h. Cells were lysed in 1× TBS with protease inhibitor (Roche) by sonication (2 min, 30% Amp, 5 s ON and 5 s OFF). The lysate was centrifuged at 21,100g for 10 min at 4 °C. The supernatant (TBS-soluble fraction) was transferred into fresh tubes and used for downstream seeding activity, western blot and IP analysis.
Western blot analysis
TBS-soluble samples were incubated with reducing 6× Laemmli SDS buffer (Alfa Aesar, J61337) at 95 °C for 10 min for denaturing conditions or 4× NuPAGE sample buffer (Invitrogen NP0007) for non-denaturing conditions and then loaded on 4–12% NuPAGE Novex gels (Invitrogen). Nitrocellulose membranes were used to transfer proteins and blocked with 5% BSA in TBS with 0.01% tween followed by overnight incubation of primary antibodies (HT7 (Thermo Fisher, MN1000; 1:1,000 dilution), anti-Bassoon (Millipore, ABN255; 1:1,000 dilution), MC1 (Peter Davies; 1:1,000 dilution), anti-total tau (DAKO, A0024; 1:5,000 dilution), PHF1 (Peter Davies; 1:1,000 dilution), anti-Actin (Abcam, ab8227; 1:2,000 dilution), pThr231 (Millipore, MAB5450; 1:1,000 dilution) and Vinculin (Sigma, V9131; 1:1,000 dilution)) diluted in the blocking solution. Horseradish peroxidase (HRP) secondary antibodies (goat anti-mouse HRP conjugated (Invitrogen, 626820; 1:5,000 dilution) and goat anti-rabbit HRP conjugated (Invitrogen, 31460; 1:5,000 dilution)) were incubated for 1 h at RT and the proteins were detected with Supersignal West Pico (Thermo Scientific, 34580) and imaged by using iBright 1500 (Invitrogen). Western blots were analyzed using ImageJ (NIH, v1.53i).
Drosophila stocks and genetics
D. melanogaster stocks and crosses were maintained on Nutri-fly Bloomington formulation (Genesee Scientific) at 25 °C in a 12-h light/dark cycle. All the fly experiments were performed at day 30 after eclosion. Transgene overexpression was achieved with the Gal4/UAS system, using GMR-Gal4 and GMR-TauP301L lines (Bloomington Drosophila Stock Center, 9146 and 51377, respectively)56. For human BSN overexpression, full-length BSN WT and p.Pro3866Ala mutant sequences were cloned downstream of the Gal4-responsive upstream activating sequences into the pUAST plasmid (VectorBuilder) and then microinjected in fly embryos (BestGene).
Eye phenotype quantification, western blot and seeding
For light microscope imaging, adult flies were immobilized at −80 °C, and then mounted for visualization. Flies were then imaged using a Leica DMC6200 camera with a ×10 objective, with a white light falling on each ommatidium until observing a single reflection spot in its center. Images were captured and stacked using Zerene Stacker (v1.01, Zerene Systems). For eye phenotypic scoring, the Flynotyper plug-in was used on ImageJ as previously described57.
Adeno-associated virus production and injections
For shRNA, sequences for mouse Bsn shRNA (CCTAACGCTTTCCTCTGACAT) and scramble shRNA (CCTAAGGTTAAGTCGCCCTCG) were used. shRNA sequences were cloned downstream of the U6 promoter and packaged into AAV9 from VectorBuilder.
For in vivo tau propagation experiments, the EGFP-P2A-hTau(2N4R)P301L sequence was cloned downstream of the CMV promoter and packaged into AAV9 (VectorBuilder). For Bsn downregulation, neonatal (P0) PS19 and WT mice were injected with the AAV scramble or shRNA Bsn sequence. Animals were euthanized at 4, 6 or 9 months after injections. For in vivo tau propagation experiments, neonatal WT C57B6/J mice were injected with AAV encoding either scramble or shRNA Bsn sequences (n = 4 for each group, 2 males and 2 females per group). After 12 weeks, mice were intracranially injected with an AAV encoding EGFP-P2A-hTau(2N4R)P301L into the hippocampus (1 μl in the left hemisphere). Mice were anesthetized with isoflurane (2%) and AAV injections at a rate of 0.5 μl min−1 were made at the following coordinates from bregma: A/P, −2 mm; M/L, −1.5 mm; D/V, −1.5 mm. Head skin was sutured, and mice were allowed to recover on a warming incubator. Mice received meloxicam for 2 d after surgery.
Electrophysiology
Six-month-old WT (10–11 males and 10–11 females) and PS19 (10–13 males and 9–11 females) littermates were used. Hippocampal slices of 300 µm in thickness were cut at 0.1 mm s−1 with a Leica VT1200 vibratome in ice-cold oxygenated external solution containing a sucrose-based artificial cerebrospinal fluid (aCSF; 194 mM sucrose, 30 mM NaCl, 26 mM NaHCO3, 10 mM glucose, 4.5 mM KCl, 0.5 mM NaH2PO4 and 1 mM MgCl2, pH 7.4) bubbled with 95% O2/5% CO2. Before cutting, mice were anesthetized with isoflurane and perfused transcardially with 10 ml of cold aCSF solution. The brains were quickly removed and blocked. After cutting, slices were transferred to an incubation chamber containing oxygenated aCSF solution at 33 °C for 1 h. Slices were then kept at RT until recording. Recordings were done at 30–32 °C in a submersion chamber perfused (1–2 ml min−1) with aCSF solution comprising 124 mM NaCl, 4.5 mM KCl, 1.2 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, 26 mM NaHCO3 and 10 mM glucose, continuously bubbled with 95% O2/5% CO2 at a pH of 7.4 and 310 mOsm.
Input–output, paired-pulse ratio and long-term potentiation recordings
For input–output curves and LTP experiments, fEPSPs evoked by Schaffer collateral stimulation with stainless-steel stereotrodes (1 MΩ, P1 Technologies) were recorded in current-clamp mode with micropipettes filled with 1 M NaCl using a Multiclamp 700B amplifier and Clampex software (Molecular Devices). Signals were low-pass filtered at 2 kHz and digitized at 50 kHz. The recording micropipette was placed in the CA1 region of the hippocampus. The intensity of the stimulator was increased stepwise until a maximal response was obtained using a constant current isolated stimulator (Digitimer). The slope of the fEPSP (mV/ms) was measured. PPR measurements were obtained every 20 s at a 40-ms interstimulus interval. The LTP protocol consisted of 10 min of stable baseline: 30 pulses every 20 s (stimulus strengths were <50% of the strength evoking a maximal response); 1 min conditioning: trains (10 pulses at 100 Hz) repeated four times every 20 s; then a 60 min post-conditioning period at the same baseline stimulation frequency: The synaptic strength change was measured from the slope of the fEPSP and data were expressed as a percentage of change with respect to the average baseline.
Behavioral test
Nine-month-old PS19 (17 males and 20 females) and WT (23 males and 19 females) littermates were used. Mice were weighed, and the resting core body temperature was measured by inserting a lubricated rectal probe (Bioseb) ~1 cm into the rectum for 10 s. For the frailty examination, mice were assessed for the presence or absence of 26 different characteristics as described before58, with modifications. A score of 0 was given if the mouse had no sign of the deficit, 0.5 if there was a mild deficit and 1 if there was a severe deficit. Grip strength of the forelimbs (front two paws) and all limbs (four paws) was evaluated using the Grip Strength Meter (Bioseb, BIO-GS3). Following the manufacturer’s protocol, mice were held by the tail and lowered toward the apparatus and allowed to grab the metal grid using two or four paws. The mice were pulled backward horizontally, and the force applied to the grid just before they lost their grip was recorded as the peak tension (converted to grams by the transducer). Peak force was measured twice in succession for each mouse for the front two paws and all four paws. The mean value of both trials was used for analysis. Mice were given a minimum break of 5 min between trials.
Magnetic resonance imaging
Nine-month-old PS19 (eight males and seven females) and WT (six males and five females) littermates were used for MRI. T2-weighted high-resolution structural images were acquired in a horizontal bore 9.4 Tesla BioSpec preclinical MRI system (Bruker BioSpin MRI, Germany) equipped with shielded gradients (maximum gradient strength, 660 mT/m; rise time, 4,570 T/m/s) and 1H mouse cryogenic surface coil (Cryoprobe, Bruker, Biospin). Two-dimensional T2-weighted (Bruker, T2 Turbo RARA) images were acquired using the following parameters: TE/TR, 43.67/7,600 ms; rare factor, 8; matrix size, 256 × 256; voxel size, 60 × 60 × 200 µm3; number of slices, 72; slice thickness, 200 µm; number of averages, 6; acquisition time, 25 min. Analysis was performed using IMARIS (Bitplane, v9.2). Mice were anesthetized under 3% isoflurane and positioned in an MRI-compatible head holder to minimize motion artifacts. Anesthesia was then maintained at 1.5% isoflurane in 100% O2 throughout imaging. The respiration rate was monitored using a pressure pad placed under the animal abdomen, and animal body temperature was maintained by a warming pad (37 °C) placed under the animal. The high-resolution in vivo T2-weighted images were oriented to Badhwar hippocampal atlas space59, corrected for noise60 and skull stripped using STAPLE algorithm61. The skull stripped brain volumes were corrected for B1 field inhomogeneity using N4 bias field correction algorithm and then registered to the Badhwar hippocampal atlas non-linearly using the Symmetric diffeomorphic image registration with cross-correlation (SyN) algorithm implemented in ANTs62,63,64. The third ventricle, fourth ventricle and lateral ventricle were combined as a single region of interest in atlas space and then transformed to individual in vivo T2-weighted image space using an inverse transform matrix and deformation map, which were generated during the forward registration. Using the registered region of interest (ventricle) as a prior label and the sample-specific T2-weighted image as a reference image, additional improvement in registration/segmentation was achieved using ANTs Atropos tool65. For each sample, final segmentation results were manually inspected for missing data registration. Using the brain mask, total intracranial volume was extracted with the FSL ‘fslstats’ tool, and using the segmented ventricle, total ventricle volume was also extracted with the fslstats tool.
To investigate group differences in ventricle volume, a general linear model was used. The independent between-group assessment was corrected for the effect of total intracranial volume. A post hoc test was conducted to further understand the sensitivity of ventricle size in terms of groupwise comparisons. The analysis was performed in SPSS (IBM, SPSS, version 27). To account for multiple comparisons across four groups, FDR correction using Benjamini–Hochberg criterion (α = 0.05) was used (pFDR < 0.05).
Statistics and reproducibility
No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications23,39,66,67. All statistical analysis and graph designs were performed using GraphPad Prism 9. Results in column graphs represent the mean ± s.e.m. Student’s t-test, one-way ANOVA and two-way ANOVA tests were performed as necessary. For all tests, an alpha value of 0.05 was used to determine statistical significance. Data distribution was assumed to be normal but this was not formally tested. Data collection and analysis were performed blind to the conditions of the experiments. No animals or data points were excluded, and outlier analysis was not performed.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
References
Alonso, A. C., Li, B., Grundke-Iqbal, I. & Iqbal, K. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 5, 375–384 (2008).
Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121–1159 (2001).
Pooler, A. M., Phillips, E. C., Lau, D. H., Noble, W. & Hanger, D. P. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389–394 (2013).
Yamada, K. et al. Neuronal activity regulates extracellular tau in vivo. J. Exp. Med. 211, 387–393 (2014).
Wu, J. W. et al. Neuronal activity enhances tau propagation and tau pathology in vivo. Nat. Neurosci. 19, 1085–1092 (2016).
Takeda, S. et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain. Nat. Commun. 6, 8490 (2015).
Tanaka, Y. et al. Seeding activity-based detection uncovers the different release mechanisms of seed-competent tau versus inert tau via lysosomal exocytosis. Front Neurosci. 13, 1258 (2019).
Eftekharzadeh, B. et al. Tau protein disrupts nucleocytoplasmic transport in Alzheimer’s disease. Neuron 99, 925–940 (2018).
Ittner, L. M., Ke, Y. D. & Gotz, J. Phosphorylated tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 284, 20909–20916 (2009).
Ittner, L. M. et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 142, 387–397 (2010).
McInnes, J. et al. Synaptogyrin-3 mediates presynaptic dysfunction induced by tau. Neuron 97, 823–835 (2018).
Sohn, P. D. et al. Pathogenic tau impairs axon initial segment plasticity and excitability homeostasis. Neuron 104, 458–470 (2019).
Vanderweyde, T. et al. Interaction of tau with the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity. Cell Rep. 15, 1455–1466 (2016).
Morris, M., Maeda, S., Vossel, K. & Mucke, L. The many faces of tau. Neuron 70, 410–426 (2011).
Liu, C., Song, X., Nisbet, R. & Gotz, J. Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions and highlights a putative role for 2N Tau in disease. J. Biol. Chem. 291, 8173–8188 (2016).
Maziuk, B. F. et al. RNA-binding proteins colocalize with small tau inclusions in tauopathy. Acta Neuropathol. Commun. 6, 71 (2018).
Choi, H. et al. Acetylation changes tau interactome to degrade tau in Alzheimer’s disease animal and organoid models. Aging Cell 19, e13081 (2020).
Wang, P. et al. Tau interactome mapping based identification of Otub1 as tau deubiquitinase involved in accumulation of pathological tau forms in vitro and in vivo. Acta Neuropathol. 133, 731–749 (2017).
Gunawardana, C. G. et al. The human tau interactome: binding to the ribonucleoproteome, and impaired binding of the proline-to-leucine mutant at position 301 (P301L) to chaperones and the proteasome. Mol. Cell Proteomics 14, 3000–3014 (2015).
Wang, X. et al. Tau interactome analyses in CRISPR–Cas9 engineered neuronal cells reveal ATPase-dependent binding of wild-type but not P301L tau to non-muscle myosins. Sci. Rep. 9, 16238 (2019).
Tracy, T. E. et al. Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration. Cell 185, 712–728 (2022).
Annamneedi, A. et al. Ablation of the presynaptic organizer Bassoon in excitatory neurons retards dentate gyrus maturation and enhances learning performance. Brain Struct. Funct. 223, 3423–3445 (2018).
Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337–351 (2007).
Holmes, B. B. et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl Acad. Sci. USA 111, E4376–E4385 (2014).
Hnasko, R., Lin, A., McGarvey, J. & Stanker, L. Enhanced detection of infectious prions by direct ELISA from the brains of asymptomatic animals using DRM2-118 monoclonal antibody and Gdn-HCl. J. Immunol. Methods 456, 38–43 (2018).
Kim, C. et al. Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer’s disease. Sci. Transl. Med. 14, eabg0253 (2022).
Hodes, R. J. & Buckholtz, N. Accelerating medicines partnership: Alzheimer’s disease (AMP-AD) knowledge portal aids alzheimer’s drug discovery through open data sharing. Expert Opin. Ther. Targets 20, 389–391 (2016).
Ertekin-Taner, N. Identifying therapeutic targets for Alzheimer’s disease with big data. Neurodegener. Dis. Manag 7, 101–105 (2017).
Okerlund, N. D. et al. Bassoon controls presynaptic autophagy through Atg5. Neuron 93, 897–913 (2017).
Waites, C. L. et al. Bassoon and Piccolo maintain synapse integrity by regulating protein ubiquitination and degradation. EMBO J. 32, 954–969 (2013).
Montenegro-Venegas, C. et al. Bassoon inhibits proteasome activity via interaction with PSMB4. Cell. Mol. Life Sci. 78, 1545–1563 (2021).
Yabe, I. et al. Mutations in Bassoon in individuals with familial and sporadic progressive supranuclear palsy-like syndrome. Sci. Rep. 8, 819 (2018).
Hashida, H. et al. Cloning and mapping of ZNF231, a novel brain-specific gene encoding neuronal double zinc finger protein whose expression is enhanced in a neurodegenerative disorder, multiple system atrophy. Genomics 54, 50–58 (1998).
Schattling, B. et al. Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. Nat. Neurosci. 22, 887–896 (2019).
Wu, M. et al. The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases. Transl. Neurodegener. 10, 45 (2021).
Zhou, L. et al. Tau association with synaptic vesicles causes presynaptic dysfunction. Nat. Commun. 8, 15295 (2017).
Olzscha, H. et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67–78 (2011).
Wegmann, S. et al. Experimental evidence for the age dependence of tau protein spread in the brain. Sci. Adv. 5, eaaw6404 (2019).
Patel, H. et al. Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiol. Aging 109, 52–63 (2022).
Wu, T. et al. Complement C3 is activated in human AD brain and is required for neurodegeneration in mouse models of amyloidosis and tauopathy. Cell Rep. 28, 2111–2123 (2019).
Altrock, W. D. et al. Functional inactivation of a fraction of excitatory synapses in mice deficient for the active zone protein Bassoon. Neuron 37, 787–800 (2003).
Tai, H. C. et al. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin–proteasome system. Am. J. Pathol. 181, 1426–1435 (2012).
Nagaishi, M., Yokoo, H. & Nakazato, Y. Tau-positive glial cytoplasmic granules in multiple system atrophy. Neuropathology 31, 299–305 (2011).
Wang, Y. et al. The release and trans-synaptic transmission of tau via exosomes. Mol. Neurodegener. 12, 5 (2017).
Lashuel, H. A. Rethinking protein aggregation and drug discovery in neurodegenerative diseases: why we need to embrace complexity? Curr. Opin. Chem. Biol. 64, 67–75 (2021).
Fichou, Y. et al. Cofactors are essential constituents of stable and seeding-active tau fibrils. Proc. Natl Acad. Sci. USA 115, 13234–13239 (2018).
Scheres, S. H., Zhang, W., Falcon, B. & Goedert, M. Cryo-EM structures of tau filaments. Curr. Opin. Struct. Biol. 64, 17–25 (2020).
Falcon, B. et al. Tau filaments from multiple cases of sporadic and inherited Alzheimer’s disease adopt a common fold. Acta Neuropathol. 136, 699–708 (2018).
Sanyal, A. et al. Alpha-synuclein is a target of Fic-mediated adenylylation/AMPylation: possible Implications for Parkinson’s disease. J. Mol. Biol. 431, 2266–2282 (2019).
Peck Justice, S. A. et al. Mutant thermal proteome profiling for characterization of missense protein variants and their associated phenotypes within the proteome. J. Biol. Chem. 295, 16219–16238 (2020).
Mohammed, H. et al. Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes. Nat. Protoc. 11, 316–326 (2016).
Papachristou, E. K. et al. A quantitative mass spectrometry-based approach to monitor the dynamics of endogenous chromatin-associated protein complexes. Nat. Commun. 9, 2311 (2018).
Bengoa-Vergniory, N. et al. Tau-proximity ligation assay reveals extensive previously undetected pathology prior to neurofibrillary tangles in preclinical Alzheimer’s disease. Acta Neuropathol. Commun. 9, 18 (2021).
Walsh, I., Martin, A. J., Di Domenico, T. & Tosatto, S. C. ESpritz: accurate and fast prediction of protein disorder. Bioinformatics 28, 503–509 (2012).
Kyte, J. & Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157, 105–132 (1982).
Karsten, S. L. et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron 51, 549–560 (2006).
Iyer, J. et al. Quantitative assessment of eye phenotypes for functional genetic studies using Drosophila melanogaster. G3 6, 1427–1437 (2016).
Whitehead, J. C. et al. A clinical frailty index in aging mice: comparisons with frailty index data in humans. J. Gerontol. A Biol. Sci. Med. Sci. 69, 621–632 (2014).
Badhwar, A., Lerch, J. P., Hamel, E. & Sled, J. G. Impaired structural correlates of memory in Alzheimer’s disease mice. Neuroimage Clin. 3, 290–300 (2013).
Coupe, P. et al. An optimized blockwise nonlocal means denoising filter for 3D magnetic resonance images. IEEE Trans. Med. Imaging 27, 425–441 (2008).
Jorge Cardoso, M. et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Med. Image Anal. 17, 671–684 (2013).
Tustison, N. J. et al. N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging 29, 1310–1320 (2010).
Avants, B. B., Epstein, C. L., Grossman, M. & Gee, J. C. Symmetric diffeomorphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med. Image Anal. 12, 26–41 (2008).
Avants, B. B. et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54, 2033–2044 (2011).
Avants, B. B., Tustison, N. J., Wu, J., Cook, P. A. & Gee, J. C. An open-source multivariate framework for n-tissue segmentation with evaluation on public data. Neuroinformatics 9, 381–400 (2011).
Lasagna-Reeves, C. A. et al. Reduction of Nuak1 decreases tau and reverses phenotypes in a tauopathy mouse model. Neuron 92, 407–418 (2016).
Jadhav, V. S. et al. Trem2 Y38C mutation and loss of Trem2 impairs neuronal synapses in adult mice. Mol. Neurodegener. 15, 62 (2020).
Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
Deutsch, E. W. et al. The ProteomeXchange consortium in 2020: enabling ‘big data’ approaches in proteomics. Nucleic Acids Res. 48, D1145–D1152 (2020).
Perez-Riverol, Y. et al. PRIDE inspector toolsuite: moving toward a universal visualization tool for proteomics data standard formats and quality assessment of proteomexchange datasets. Mol. Cell Proteomics 15, 305–317 (2016).
Acknowledgements
This work was supported by NIH/NINDS 1R01NS119280, NIH/NIA 1R01AG059639 and AARGD-591887 grants, the Department of Defense award AZ180006 to C.A.L.-R., AARFD-21-847663 to P.M., the Indiana Clinical and Translational Sciences Institute, the Precision Health Initiative in AD at Indiana University and the Stark Neurosciences Research Institute (SNRI). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. AD and PSP tissues for this research were provided by the Johns Hopkins University Morris Udall Parkinson’s Disease Center of Excellence (NINDS P50NS38377), Alzheimer Disease Research Center (NIH P30AG066507) and BIOCARD (NIH U19AG033655 to J.T.). Mass spectrometry was provided by the IUSM Proteomics Core Facility. We acknowledge the in vivo imaging core at Indiana University and the electrophysiology core at the SNRI. The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org/). We thank Dr. Louise Pay for constant feedback on the manuscript.
Author information
Authors and Affiliations
Contributions
P.M. and C.A.L.-R. conceived and designed the project with contributions from H.P., Yanwen You, N.J., A.P., A.L.-G., X.T., Yingjian You, G.V.D.P., X.H., S.D., A.W., S.S.S. and J.C. performing experiments. J.R.-O. and J.T. provided human AD and PSP samples. S.S.S. and Y.-C.W. performed MRI and data analysis. H.P. and D.M. performed all behavioral testing and analysis. S.D., S.M. and J.-C.R. performed EM analysis. X.H. and J.Z. provided bioinformatic results and analysis. G.V.D.P. and B.A. conducted electrophysiology experiments and analysis. A.W. and A.M. performed the mass spectrometry and provided the analysis. P.M., X.T. and H.P. conducted the astrogliosis and microgliosis experiments and data analysis. Yanwen You performed the tau-seeding activity assays and BSN bioinformatic analysis. P.M., Yanwen You, N.J., A.P. and A.L.-G. conducted the biochemical and histopathological characterization in PS19 mice. P.M. and H.P. performed all molecular biology experiments in HEK cells. P.M., J.C. and G.L. performed the biochemical and histopathological characterization and analysis of AD and PSP cases. P.M. designed and performed all Drosophila experiments, tau spreading in vivo experiments and synaptic and biochemical analysis of SEC fractions. P.M. and C.A.L.-R. wrote the manuscript with contributions from all the authors.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Peer review
Peer review information
Nature Neuroscience thanks the anonymous reviewers for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data
Extended Data Fig. 1 HMW tau seed represents a low percentage of total tau in the PS19 mouse brain.
a, Cells were gated on a FSC-A vs SSC-A plot. From the gated cells population, single cells were gated on a SSC-W vs SSC-H plot. From the gated single cells population, FRET positive cells were gated on a BV421-A vs BV510-A plot after compensation. The FRET-positive population lies in the region with the same BV421-A intensity, but higher BV510-A intensity, with the boundary between positive and negative determined by excluding the signal from a negative control. b, Schematic of aggregated tau denaturation by guanidine HCl (Gdn HCl). c, hTau present in F9 (gray bars) as a percentage of total brain lysates (green bars) before and after denaturation with 3 M of Gdn-HCl. Total human tau levels were assayed by ELISA. Data represent the mean ± s.e.m. The experiment was performed with n = 3.
Extended Data Fig. 2 Bassoon is associated with tau pathology in PS19 mice.
a, Representative immunofluorescence and colocalization for BSN (red), PHF1 (green), nuclei (cyan), and merge (yellow), in 3-, 6- and 9-month-old wild-type and PS19 mouse cortexes. Scale bar: 200 µm for main images and 50 µm for insets. Merge image for PS19 includes orthogonal image of reconstructed three-dimensional views. Colocalization analysis was performed to determine pixel intensity correlation between PHF1 and BSN. b, Pearson’s correlation of BSN and PHF1 intensity in 3-, 6- and 9-month-old wild-type and PS19 mouse cortexes. c, 3-month-old PS19 mouse sections immunostained against PHF1, BSN, and Syn-1 (upper panels), and colocalization of PHF1 and BSN (colored yellow; lower left panel). PHF1/BSN colocalization was re-colocalized with the Syn-1 channel to obtain a final triple-colocalization between PHF1/BSN and Syn-1 (lower middle and right panels). d, Percentage of colocalization between PHF1/BSN puncta and Syn-1. Data are the mean ± s.e.m. Experiments were performed with n = 3 (a–d). Significance was determined by one-way ANOVA (b).
Extended Data Fig. 3 Bassoon colocalizes with a pathological tau species in human AD and PSP cases.
a, b, Immunofluorescence, merge and colocalization images of BSN (red) and pTauS396/S404 (PHF1, green) in human AD (from middle frontal gyrus, MFG) (a), and PSP (from pons) (b), and healthy control subjects from MFG and pons, respectively. Merge image includes orthogonal image of reconstructed three-dimensional views. Scale bar: 200 µm for main images and 50 µm for insets. Experiments were performed in triplicates for AD and PSP cases.
Extended Data Fig. 4 Bassoon overexpression increases tau accumulation in vitro and in a Drosophila model of tauopathy.
a–c, hTau levels by ELISA (a), Western blot of total tau (b), seeding activity (c) from HEK cells overexpressing hTauWT or hTauP301S. Western blot membrane was overexposed in the upper level for better visualization of oligomeric tau (denoted by the asterisk*). d, Location of BSN peptides detected by IP−mass spec. e, Representative images, and quantification of 6X-His immunofluorescences from HEK cells overexpressing hTauP301S and 6X-His-BSN N- or C- terminal fragments (BSN-N or BSN-C, respectively). f, Disordered residues of human and mouse bassoon. 85.1% of residues in human BSN and 85.8% of residues in mouse BSN were predicted to be disordered. g, Hydrophobicity profile of bassoon using method of Kyte & Doolittle. Average hydrophobicity is −0.81 for human BSN, and −0.85 for mouse BSN, h, Western blot confirming the overexpression of the UAS-BSN under the GMR-Gal4 driver in different fly lines. i, Western blot for BSN of co-immunoprecipitation (Co-IP) of human tau (HT7) from hTauP301L/BSNWT and hTauP301L/BSNmut fly head lysates. Experiments were repeated three times with similar results (h, i). j, k, Western blot (j), of the level of HMW and 117 kDa MC1 detected and quantified (k), in hTauP301L, hTauP301L/BSNWT and hTauP301L/BSNmut fly head lysates. Each sample is a pool of 20 fly brains from 3 different eclosion events. l, m Western blot (l), and quantification of misfolded tau (MC1) (m), in fly lysates denatured by increasing concentrations of guanidine HCl, in hTauP301L, hTauP301L/BSNWT, and hTauP301L/BSNmut head lysates. Data are the mean ± s.e.m. Experiments were performed with n = 3 (a–c, e, j–m). Significance was determined by unpaired two-tailed Student’s t-test (a, c, e) and one-way ANOVA (k, m).
Extended Data Fig. 5 Murine bassoon downregulation does not produce gross brain abnormalities.
a, Western blot and quantification of BSN downregulation in WT mice. b, Detection of BFP2 reporter in AAV scramble and AAV shBSN mice, confirming the widespread expression of both sequences. c, H&E staining of WT mice injected with a scramble and shBSN shRNA. d, BSN and Syn-1 immunofluorescence in WT mouse cortexes injected scramble and shBSN shRNA, and mean intensity of BSN and Syn-1. Data are shown as the mean ± s.e.m. Experiments were performed with n = 8 (a–d). Significance was determined by unpaired two-tailed Student’s t-test (a), and one-way ANOVA (d).
Extended Data Fig. 6 Reducing bassoon levels mitigate tau pathology in male and female PS19 mice.
a, b, Western blot (a), and quantification of BSN downregulation (b), in PS19 mice. c, Quantification of MC1 immunostaining in shBSN and scramble, of PS19 mice by sex as a percentage of area. d, e, Quantification of hippocampal immunofluorescence of IBA1 (d), and GFAP (e), in WTscramble, WTshBSN, PS19scramble, and PS19shBSN mice, separated by sex. f, g, Western blot quantification of pTauS396/S404 (PHF1) (f), and pTau Thr231 (g), in shBSN and scramble PS19 mouse brain lysate, separate by sex. h, i, Total human tau levels by ELISA (h), and tau-seeding activity (i), in shBSN and scrambled PS19 mouse brain lysates, separated by sex. Data are shown as the mean ± s.e.m. Experiments were performed with n = 8 (a, b), and n = 4 per sex (c–i). Significance was determined by unpaired two-tailed Student’s t-test (b, c, f–i), and one-way ANOVA (d, e).
Extended Data Fig. 7 Increased susceptibility to PK degradation of misfolded tau aggregates after bassoon downregulation in PS19 mice.
a, b, Proteinase K sensitivity assay (a), and quantification (b), of MC1 IHC intensity at 0, 10, and 45 sec after PK treatment in scramble and shBSN PS19 brain sections. Scale bar: 100 µm for main pictures and 10 µ for insets. Data are shown as the mean ± s.e.m. Experiments were performed with n = 3 (a, b). Significance was determined by unpaired two-tailed Student’s t-test (b).
Extended Data Fig. 8 Rescue of synaptic integrity in PS19 after bassoon downregulation.
a, Pearson’s correlation of PSD95 and Syn-1 in WTscramble, WTshBSN, PS19scramble, and PS19shBSN mice, separated by sex. b, Representative immunofluorescence in scramble and shBSN PS19 mice for misfolded tau (MC1), and Syn-1 protein. Colocalization analysis was performed to determine pixel intensity correlation between MC1 and Syn-1. Scale bar: 50 µm for main panels and 10 µm for insets. c, Pearson’s correlation of MC1 and Syn-1 immunostainings in scramble and shBSN PS19 mice. Data are shown as the mean ± s.e.m. Experiments were performed with n = 4 per sex (a), and n = 8 (b, c). Significance was determined by one-way ANOVA (a), and unpaired two-tailed Student’s t-test (c).
Extended Data Fig. 9 Bassoon downregulation improves behavioral and electrophysiological impairments in PS19 males and females.
a, b, Average of fEPSP slope from minute 60 to 70 by sex (a) and paired-pulse ratio (PPR) (b), in 6-month-old WT and PS19 mice injected with shBSN or scramble shRNA. c-f, 2-paw test (c), 4-paw test (d), body temperature (e), and frailty test (f), in 9-month-old WT and PS19 mice injected with shBSN or scramble shRNA. g-j, Quantification of MC1 immunostaining as a percentage of area (g), pTauS396/S404 (PHF1) protein levels (h), pTau Thr231 protein levels (i), and total human tau levels by ELISA (j), in shBSN and scrambled PS19 male and female mouse brain lysates. Data represent the mean ± s.e.m. Experiments were performed with n = 7 for males and n = 4 for females for WTscramble, n = 4 for males and n = 6 for females for PS19scramble, n = 7 for males and n = 4 for females for WTshBSN, and n = 6 for males and n = 5 for females for PS19shBSN mice (a), n = 5 for males and n = 6 for females for WTscramble, n = 5 for males and n = 5 for females for PS19scramble, n = 5 for males and n = 5 for females for WTshBSN, and n = 5 for males and n = 6 for females for PS19shBSN mice (b), n = 10 for males and n = 10 for females for WTscramble, n = 9 for males and n = 12 for females for PS19scramble, n = 13 for males and n = 9 for females for WTshBSN, and n = 8 for males and n = 8 for females for PS19shBSN mice (c-f), and n = 4 per sex (g-j). Significance was determined by one-way ANOVA (a–f), and unpaired two-tailed Student’s t-test (g–j).
Extended Data Fig. 10 Downregulation of bassoon corresponds to reduced ventricular volume and an increment of hippocampal volume in PS19 mice.
a–c, In vivo Magnetic resonance imaging (MRI) (a), quantification of ventricular (b), and hippocampal volume normalized to total brain volume (c), in 9-month-old WT and PS19 mice injected with shBSN or scramble shRNA. Data represent the mean ± s.e.m. Experiments were performed with n = 7 for WTscramble, n = 8 for PS19scramble, n = 4 for WTshBSN, and n = 7 for PS19shBSN mice. Significance was determined by one-way ANOVA (b, c). b, c, for box plots, midlines represent the median, boundaries are interquartile range, and the whiskers are minimum-maximum.
Supplementary information
Supplementary Information
Supplementary Table 1
Supplementary Data 1
Tau-seed interactome and tau monomer interactome. Tau monomer interactome in PS19 mouse brains. Monomeric tau isolated from F17 from PS19 brain homogenates was subjected to quantitative mass spectrometry; n = 3. Tau-seed interactome in PS19 mouse brains. HMW tau seed isolated from F9 from PS19 brain homogenates was subjected to quantitative mass spectrometry; n = 3.
Supplementary Data 2
DAVID functional annotation and interactome versus nominated intersection. DAVID functional annotation clustering of tau-seed interactors. DAVID functional annotation chart of tau-seed interactors. DAVID functional annotation clustering of tau-monomer interactors. DAVID functional annotation chart of tau-monomer interactors. Synaptic interactors of the tau seed and monomeric fractions.
Source data
Source Data Fig. 1
Unprocessed western blots and/or gels.
Source Data Fig. 1
Statistical source data.
Source Data Fig. 2
Unprocessed western blots and/or gels.
Source Data Fig. 2
Statistical source data.
Source Data Fig. 3
Unprocessed western blots and/or gels.
Source Data Fig. 3
Statistical source data.
Source Data Fig. 4
Statistical source data.
Source Data Fig. 5
Unprocessed western blots and/or gels.
Source Data Fig. 5
Statistical source data.
Source Data Fig. 6
Statistical source data.
Source Data Fig. 7
Unprocessed western blots and/or gels.
Source Data Fig. 7
Statistical source data.
Source Data Extended Data Fig. 1
Statistical source data.
Source Data Extended Data Fig. 2
Statistical source data.
Source Data Extended Data Fig. 4
Unprocessed western blots and/or gels.
Source Data Extended Data Fig. 4
Statistical source data.
Source Data Extended Data Fig. 5
Unprocessed western blots and/or gels.
Source Data Extended Data Fig. 5
Statistical source data.
Source Data Extended Data Fig. 6
Unprocessed western blots and/or gels.
Source Data Extended Data Fig. 6
Statistical source data.
Source Data Extended Data Fig. 7
Statistical source data.
Source Data Extended Data Fig. 8
Statistical source data.
Source Data Extended Data Fig. 9
Statistical source data.
Source Data Extended Data Fig. 10
Statistical source data.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Martinez, P., Patel, H., You, Y. et al. Bassoon contributes to tau-seed propagation and neurotoxicity. Nat Neurosci 25, 1597–1607 (2022). https://doi.org/10.1038/s41593-022-01191-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41593-022-01191-6
This article is cited by
-
Evolving prion-like tau conformers differentially alter postsynaptic proteins in neurons inoculated with distinct isolates of Alzheimer’s disease tau
Cell & Bioscience (2023)
-
Reply: Soluble oligomers or insoluble fibrils?
Acta Neuropathologica (2023)
